| Report ID | 273864 |
| Drug Identification Number | 02518910 |
| Brand name | GLN-APREMILAST |
| Common or Proper name | GLN-APREMILAST |
| Company Name | GLENMARK PHARMACEUTICALS CANADA INC. |
| Market Status | MARKETED |
| Active Ingredient(s) | APREMILAST |
| Strength(s) | 30MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 60's |
| ATC code | L04AA |
| ATC description | IMMUNOSUPPRESSANTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2025-12-09 |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-02-13 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1600 STEELES AVE. W., SUITE 407 CONCORD, ONTARIO CANADA L4K 4M2 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2026-02-13 | French | Compare |
| v3 | 2026-02-13 | English | Compare |
| v2 | 2025-12-09 | French | Compare |
| v1 | 2025-12-09 | English | Compare |
Showing 1 to 4 of 4